16 February 2023
Benchmark Holdings plc
("Benchmark" or the "Company")
Result of AGM
Benchmark Holdings plc, the aquaculture health, nutrition and genetics business, announces that at the Company's Annual General Meeting, held at 3.00 p.m. today, with the exception of Resolutions 15 and 16, all resolutions were passed by shareholders voting on a poll. The results of the poll are set out below.
|
Res No. |
Resolution Name |
Votes For |
% |
Votes Against |
% |
Votes Total |
% I.S.C. |
Votes Withheld |
|
01 |
Reports and accounts |
574,934,271 |
100.00% |
8,379 |
0.00% |
574,942,650 |
77.77 |
2,000 |
|
02 |
Remuneration Report |
572,004,635 |
99.49% |
2,938,015 |
0.51% |
574,942,650 |
77.77 |
2,000 |
|
03 |
Reappoint Auditors |
573,033,919 |
99.67% |
1,908,731 |
0.33% |
574,942,650 |
77.77 |
2,000 |
|
04 |
Auditors remuneration |
574,925,589 |
100.00% |
13,311 |
0.00% |
574,938,900 |
77.77 |
5,750 |
|
05 |
Trond Williksen |
574,934,271 |
100.00% |
8,379 |
0.00% |
574,942,650 |
77.77 |
2,000 |
|
06 |
Kristian Eikre |
573,072,601 |
99.67% |
1,870,049 |
0.33% |
574,942,650 |
77.77 |
2,000 |
|
07 |
Septima Maguire |
574,934,271 |
100.00% |
8,379 |
0.00% |
574,942,650 |
77.77 |
2,000 |
|
08 |
Peter George |
571,410,678 |
99.39% |
3,521,323 |
0.61% |
574,932,001 |
77.77 |
12,649 |
|
09 |
Kevin Quinn |
574,934,271 |
100.00% |
8,379 |
0.00% |
574,942,650 |
77.77 |
2,000 |
|
10 |
Susan Searle |
573,072,601 |
99.67% |
1,870,049 |
0.33% |
574,942,650 |
77.77 |
2,000 |
|
11 |
Yngve Myhre |
574,934,271 |
100.00% |
8,379 |
0.00% |
574,942,650 |
77.77 |
2,000 |
|
12 |
Atle Eide |
573,068,851 |
99.67% |
1,870,049 |
0.33% |
574,938,900 |
77.77 |
5,750 |
|
13 |
Laura Lavers |
573,068,851 |
99.67% |
1,870,049 |
0.33% |
574,938,900 |
77.77 |
5,750 |
|
14 |
Allot shares |
571,916,971 |
99.47% |
3,025,679 |
0.53% |
574,942,650 |
77.77 |
2,000 |
|
15 |
pre-emption rights |
258,462,999 |
44.95% |
316,479,651 |
55.05% |
574,942,650 |
77.77 |
2,000 |
|
16 |
Additional pre-emption rights |
255,447,999 |
44.43% |
319,494,651 |
55.57% |
574,942,650 |
77.77 |
2,000 |
|
17 |
Purchase own shares |
572,977,997 |
99.67% |
1,898,423 |
0.33% |
574,876,420 |
77.76 |
68,230 |
|
18 |
Cancel share premium account |
574,935,897 |
100.00% |
6,753 |
0.00% |
574,942,650 |
77.77 |
2,000 |
The Board notes that Resolutions 15 (Disapplication of Pre-emption Rights - General) and 16 (Disapplication of Pre-emption Rights - Acquisitions and Specified Capital Investments), which were special resolutions requiring a 75% majority, did not receive sufficient support to be passed.
These resolutions were in line with the updated Pre-Emption Group's Statement of Principles and the Board considers the flexibility afforded by these authorities to be in the best interests of the Company. In accordance with Provision 4 of the UK Corporate Governance Code, the Board confirms that it will consult and continue to engage with the relevant shareholders to understand and discuss their concerns with respect to these resolutions.
Enquiries
|
|
About Benchmark
Benchmark is a market leading aquaculture biotechnology company. Benchmark's mission is to drive sustainability in aquaculture by delivering mission-critical products and solutions in genetics, advanced nutrition and health which improve yield, growth and animal health and welfare. Through a global footprint in 26 countries and a broad portfolio of products and solutions, Benchmark addresses the major aquaculture species - salmon, shrimp, sea bass and bream, and tilapia, in all the aquaculture regions around the world.
Find out more at www.benchmarkplc.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
